ASCO GU 2022

Neoadjuvant therapy in UTUC: Good options for selected patients

ADC in bladder cancer: defining the future!

Role of PARPi in urothelial cancer

PARPi in urothelial cancer: DFS advantage for the DDR+, OS data pending.

Patient selection for adjuvant Nivolumab (TPS vs. CPS)

Mature data confirm efficacy of maintenance avelumab as standard of care

Patient selection for bladder preservation

IO escalation results in improved response in met. TCC.

Follow-up data confirm OS benefit across subgroups

HER2 ERBB2 – entering precision oncology

Exciting data supports trimodality therapy

Ongoing immunotherapy innovation for mCRPC

Not practice changing, but hypothesis generating.

ADCs will be step-changing in urothelial cancers

ADC shape the therapy landscape in urothelial cancer

Enza beyond progression? Practice changing or not?

Do we need testing? Which biomarkers are of relevance?

The future of genetic testing. Somatic vs. germline? International perspectives

Theranostics – Presence and future: Vision, PSMAfore, PSMAAddition, TheraP

Triplet vs. doublet: Which patients should we consider?

Is biomarker development taking a back seat in prostate cancer?

DARO in triplet therapy for CRPC

The need for biomarker panels in biopsy decision making

PROpel & Magnitude: who wins the race?

Addition of darolutamide improves OS in met. hormone-sensitive PC

HRR testing: MAGNITUDE vs. PROpel

Subgroup analyses confirm the importance of oral daily GnRH Antagonist - relugolix

PSMA and FDG PET as biomarkers for response to LuPSMA

Triplet-therapy as a novel treatment option

Should we use arbiraterone and olaparib as 1st line treatment of mCRPC?

New therapies and molecular targets in prostate cancer

The importance of conducting HCRA

Should we use arbiraterone and niraparib as 1st line treatment of mCRPC with BRCA1/2 mutation?

PSA response correlates with OS and benefits in QoL

Is the dual hormone-backbone the future?

Where do PROpel and Magnitude agree?

Exciting new compound for mCRPC

How to improve PSMA based radioligand therapy

Is docetaxel still needed for hormone sensitive mCRPC?

PRESIDE indicates benefit of continuation ENZA + ADT

Thoughts on first line treatment options following ASCO GU 2022

Adjuvant PD1 Therapy confirms significant benefit for high-risk patients. An individual risk benefit assessment is required!

Treatment options following adjuvant PD1 Therapy: Uncertainty of choices!

Neoadjuvant IO+TKI Treatment: We need more data on efficient IO/TKI combinations

Consistent OS benefit confirmed. Consider overtreatment vs. undertreatment!

Adjuvant Pembroluzimab update in kidney cancer

Neoadjuvant avelumab/axitinib - NeoAvAx

Data gap in 2nd line RCC: what’s new?

Nivo montoherapy followed by Nivi-Ipi resuce

Update in neoadjuvant therapy for kidney cancer

Update in adjuvant therapy for kidney cancer

Frontline treatment of metastatic kidney cancer

CheckMate final OS Follow Up and health related QoL

Microbioma modification and checkpoint inhibition